Navigation Links
VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
Date:9/18/2013

MARIETTA, Ga., Sept. 18, 2013 /PRNewswire/ -- VIVEX BIOMEDICAL, INC., a biomaterials manufacturer and developer, announced today that it has successfully completed its first round of private equity financing.  The financing involved an over-subscribed offering of the Company's preferred stock, generating $7.6 million in start-up capital. 

Tracy Anderson, President and CEO of Vivex, said, "We are grateful to our shareholders and investors.  They have provided us capital to grow our rapidly expanding biosciences portfolio while allowing the executive team to focus on the strategic execution and day to day operations.  We are excited about the future of Vivex."

Start-up capital will be used to refine current and develop new products, expand its team, and identify and pursue strategic partnerships and other opportunities.  The company's patented flagship products, currently in development, include the MIAMI stem cell and mimetic pattern implants and other protected Intellectual Property.  The company's core biomaterials include demineralized bone matrix, sponge, allograft, and calcium phosphate products backed by a proprietary cleansing process that sustains bioactivity.

About VIVEX BIOMEDICAL, INC.

Vivex commenced operations in 2013 following a spin-off of the biomaterials division of Amendia, Inc., a Marietta, Georgia spinal implant manufacturer, and has since experienced rapid growth.  In support of the biologics-oriented platform, Vivex is developing a strategic portfolio of revolutionary interactive implants that nurture and guide the body's regenerative responses for accelerated healing while minimizing recuperation. The company's soon to be released flagship products range from bioresonant mimetic implants that encourage and enhance response from the body, to a revolutionary undifferentiated adult stem cell line that retains the multi-lineage potential to repair virtually any tissue type.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the federal security laws.  Forward-looking statements are only predictions and are not guarantees of performance.  You should not place undue reliance on any forward-looking statements.  

For more information, please visit the company's website at www.vivex.com or contact the company's General Counsel, Michael F. Rozmajzl, Esq., CPA., at 770.575.5221.  


'/>"/>
SOURCE VIVEX BIOMEDICAL, INC.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Reporting Guidelines For Case Reports Presented At The Congress On Peer Review And Biomedical Publication And Published In Seven Medical Journals
2. Saladax Biomedical Announces Addition to Leadership Team
3. Funding Tomorrow's Biomedical Research: California Healthcare Institute Hosts Pipeline for Life, July 15
4. The Galien Foundation Celebrates Biomedical Innovation in Fourth Galien Forum
5. David Julius Wins 2013 Dr. Paul Janssen Award for Biomedical Research
6. BioMedical Life Systems, Inc. Launches New FDA Cleared Non-Prescription TENS Device
7. Ondine Biomedical CEO Carolyn Cross Appointed Treasurer of International Photodynamic Association
8. Arteriocyte announces Launch of Compass Biomedical
9. Regenesis Biomedical Names Scott Brooks Chief Executive Officer
10. Premier Biomedical CEO Interviewed by The Wall Street Transcript
11. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... President for Public Policy for the National Organization for Rare Disorders (NORD). Dorman ... to ensure their voices are heard throughout the drug regulatory review process. , ...
(Date:2/9/2016)... YORK , Feb. 9, 2016 This ... analyzes the current and future prospects of the market ... this report include companies engaged in the manufacture of ... an executive summary with a market snapshot providing the ... scope of this report. This section also provides the ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists ... Camp Experiences SHPG ... lives of children born with rare diseases, as well as the ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> To mark the company,s founding ...
(Date:2/9/2016)... 2016 DelveInsight,s, "Protein-Tyrosine ... provides in depth insights on the pipeline ... Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Biology Technology:
(Date:1/21/2016)... 2016 --> ... research report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, ... Expression, Voice Recognition and Others), Services, Application Areas, ... 2020", published by MarketsandMarkets, the global Emotion Detection ... 22.65 Billion by 2020, at a CAGR of ...
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):